T1	Participants 1469 1482	mCRC patients
T2	Participants 79 107	metastatic colorectal cancer
T3	Participants 225 274	patients with metastatic colorectal cancer (mCRC)
T4	Participants 571 674	279 previously untreated mCRC patients treated with capecitabine, oxaliplatin and bevacizumab (CAPOX-B)
